[Federal Register Volume 71, Number 168 (Wednesday, August 30, 2006)]
[Notices]
[Pages 51624-51625]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-14423]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Prospective Grant of Exclusive License: Prophylactic Use of 
Pneumococcal Surface Adhesin A Protein as a Vaccine

AGENCY: Office of Technology Transfer; Centers for Disease Control and 
Prevention (CDC); Department of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 
CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention 
(CDC), Technology Transfer Office, Department of Health and Human 
Services (DHHS), is contemplating the grant of a worldwide, limited 
field of use, exclusive license to practice the inventions embodied in 
the patent and patent applications referred to below to Intercell, 
having a place of business in Vienna, Austria. The patent rights in 
these inventions have been assigned to the government of the United 
States of America. The patent and patent applications to the licensed 
are: U.S. Patent No. 5,422,427 entitled ``Pneumococcal Fimbrial Protein 
A,'' issued 06.06.95.

U.S. Patent No. 6,312,944 entitled ``Pneumococcal Fimbrial Protein A,'' 
issued 11.06.01.
U.S. Patent No. 5,854,416 entitled ``Streptococcus pneumoniae 37-kDa 
Surface Adhesin A Protein and Nucleic Acids Coding Therefore,'' issued 
12.29.98 (CDC Ref: E-157-91/4).
U.S. Patent No. 6,217,884 entitled ``Streptococcus pneumoniae 37-kDa 
Surface Adhesin A Protein,'' issued 04.17.01.
U.S. Patent No. 6,773,880 entitled ``Streptococcus pneumoniae 37-kDa 
Surface Adhesin A Protein,'' issued 06.05.03.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.

ADDRESSES: Requests for a copy of these patent applications, inquiries, 
comments, and other materials relating to the contemplated license 
should be directed to Thomas E. O'Toole, MPH, Chief Licensing Officer, 
Technology Transfer Office, Centers for Disease Control and Prevention 
(CDC), 4770 Buford Highway, Mailstop K-79, Atlanta, GA 30341, 
telephone: (770) 488-8600; facsimile: (770) 488-8615. Applications for 
a license filed in response to this notice will be treated as 
objections to the grant of the contemplated license. Only written 
comments and/or applications for a license which are received by CDC 
within thirty days of this notice will be considered. Comments and 
objections submitted in response to this notice will not be made 
available for public inspection, and, to the extent permitted by law, 
will not be released under the Freedom of Information Act, 5 U.S.C. 
552. A signed Confidential Disclosure

[[Page 51625]]

Agreement will be required to receive a copy of any pending patent 
application.

    Dated: August 21, 2006.
James D. Seligman,
Chief Information Officer, Centers for Disease Control and Prevention.
 [FR Doc. E6-14423 Filed 8-29-06; 8:45 am]
BILLING CODE 4163-18-P